Medical

Many patients with diabetes are painless when their blood sugar is high, and retinopathy is also silent and imperceptible. Therefore, the majority of diabetes patients should be reminded that after the diagnosis of diabetes, they must regularly screen the sugar network, and early diagnosis and treatment is the key. Early detection, early treatment and regular reexamination can avoid more than 90% of severe visual impairment.

New research by japanese scientists has found that

In today's rapidly changing world of science and technology, a research result that sounds very sci-fi will appear from time to time. No, a paper published in the journal Science Robotics belongs to this scope: a cell regeneration robot that successfully works in vivo.

The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial

Dry eye after excimer surgery is a common problem. The main reason for the occurrence of dry eye after surgery is that during excimer surgery, the production of corneal flap and the cutting of matrix cut off the sensory nerve of part of the cornea, reducing the sensory and neurotrophic functions of the cornea, leading to the reduction of reflective tear secretion and the number of blinks, which leads to the reduction of the amount of tear secretion and the stability of the tear film. The study found that the corneal nerve after surgery can be restored to the preoperative level after 6-9 months of regeneration and repair. Therefore, dry eye may be obvious at the early stage after surgery, but it will gradually reduce with corneal repair until it returns to normal.

As medicine continues to advance, there are many good drugs and options to fight cancer. Just recently, a study showed that the NALIRIFOX regimen significantly improved the overall survival of patients with advanced pancreatic ductal adenocarcinoma who had not received previous treatment.

Preoperative oxaliplatin-fluoropyrimidine chemotherapy given to colon cancer patients did not increase the risk of perioperative complications in colon cancer patients and did reduce postoperative recurrence rates, according to the results of the international phase 3/4 FOxTROT trial.

The clinical trial (PARABLE) will take place at 22 sites across the UK and is planned to recruit 192 patients at higher risk of developing heart problems. the PARABLE trial is led by researchers from the Royal Marsden Hospital, the University of Cambridge, and the Institute of Cancer Research (ICR) UK, and is managed by the Clinical Trials and Statistics Unit, funded by Cancer Research UK, at the Institute of Cancer Research (ICR). was conducted.

Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.

According to data from cohort 17 of the phase 1b COSMIC-021 trial (NCT03170960), the combination therapy of cabozantinib and atelizumab, at a mean follow-up of 25.9 months, 17% of the 30 patients in cohort 17 had significant tumour shrinkage or disappearance, giving an overall disease control rate of 60% when those with stable lesions were added. 5 patients with tumours in remission All of the patients whose tumours had shrunk by at least 30%.